GlassScriptPhysician profile
Holly E Griffin
NPI 1285025957
$3,743.09
in general payments reported to CMS, 2019-2025
26 companies · $1,953 in 2025
The $1,953 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $413 · 2023: $474 · 2024: $752 · 2025: $1,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,070 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.39 |
| Education | $108.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,227.76 | 2021-2025 | |
| Lilly USA, LLC | $418.77 | 2022-2025 | Omvoh, Taltz, Zepbound |
| Ucb, INC. | $398.00 | 2024-2025 | Bimzelx, Cimzia |
| Amgen INC. | $314.48 | 2023-2025 | Evenity, Krystexxa, Prolia |
| Novartis Pharmaceuticals Corporation | $226.01 | 2024-2025 | |
| Janssen Biotech, INC. | $182.24 | 2025 | Tremfya, Simponi Aria |
| Actelion Pharmaceuticals US, INC. | $175.15 | 2024-2025 | Opsumit, Uptravi |
| Qol Medical, LLC | $124.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.55 | 2024-2025 | Orencia |
| Sanofi-Aventis U.S. LLC | $80.98 | 2022 | |
| Aurinia Pharma U.S., INC. | $72.81 | 2023-2024 | Lupkynis |
| Ethicon US, LLC | $61.02 | 2021 | |
| Alexion Pharmaceuticals, INC. | $50.26 | 2025 | Strensiq, Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $40.53 | 2021 | |
| Pfizer INC. | $34.72 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.08 | 2024-2025 | Actemra |
| Organon LLC | $31.43 | 2024 | |
| Sandoz INC. | $26.14 | 2025 | Jubbonti |
| Depuy Synthes Sales INC. | $24.35 | 2024 | Monovisc, Orthovisc |
| Invivyd INC | $23.16 | 2025 | Pemgarda |
| Celgene Corporation | $22.71 | 2024 | Orencia |
| Sobi, INC | $21.56 | 2025 | |
| Fresenius Kabi USA, LLC | $19.03 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.49 | 2023 | Ofev |
| Mallinckrodt Hospital Products INC. | $17.05 | 2025 | Acthar |
| Radius Health, INC. | $16.29 | 2025 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.